Targeting TG levels after a first or recurrent acute coronary syndrome (ACS) event may have beneficial effects on subsequent clinical outcomes, and approximately 20% of patients may benefit from eicosapentaenoic acid (EPA) therapy.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
